Document:

exv10w5

Exhibit 10.5

Amendment No. 3 to Distribution Agreement

This Amendment No, 3 to Distribution Agreement (this “Amendment”) is effective
on July 11, 2008 (“Amendment Date”), and is entered into between Inverness
Medical Innovations North America, Inc., a Delaware corporation
(“Inverness”) having a place of business at 30 South Keller Road. Orlando, Florida 32804 (as
successor by assignment from Biosite Corporation effective April 1, 2008), and
Fisher HealthCare, a Division of Fisher Scientific Company, L.L.C.
(“FHC”), having a place of business at 9999 Veterans Memorial Drive, Houston, Texas 77038 and
amends the Distribution Agreement between the parties dated
January 1, 2006 (as amended, the “2006 Distribution
Agreement”).

     The
parties mutually agree that the 2006 Distribution Agreement shall be
amended through this Amendment on the terms and conditions below as follows:

1.
Defined Terms. Any defined terms in this Amendment shall have the same meaning
designated in
the 2006 Distribution Agreement unless otherwise expressly provided
herein.

2.
Term of Amendment. The first sentence of Section 6(a) and Section 6(a)(i) shall
be amended and
replaced in their entirety by the following:

This Agreement shall commence on the Effective Date and shall expire on December
31, 2010 (“Initial Term”). Except as otherwise set forth in this Agreement, (i)
unless either party (in such party’s sole discretion) gives to the other party
notice of non-renewal not less than six (6) months prior to the
exploration of the Initial Term, this Agreement shall be automatically extended for a period
of one (1) year following the expiration of the Initial Term (the “First
Extended Term”), and

3. Guaranteed Selling Margin
Rate (“GSMR”). The parties acknowledge and agree that
Section 5(f)(i),5(f)(ii) and 5(f)(iii) shall pe replaced in their entirety with the following:

Beginning on January 1, 2009 and continuing for the remaining duration of the
Initial Term, the-parties acknowledge and agree to the following GSMR for each
Product category as follows:

	 	 	 	 	 
	Product Category	 	GSMR
	 	 	 
	Triage® BNP Test (excluding the BNP
Tests for Beckman Systems)
	 	 	11.0	%
	D-Dimer Products
	 	 	11.0	%
	Triage® TOX Drug Screen Products
	 	 	10.5	%
	DOA Products (excluding Triage® TOX
Drug Screen Products)
	 	 	16.0	%
	Cardiac Products
	 	 	5	%

For the
purpose of determining the applicable GSMR
a “hospital” shall
mean a building or real estate improvement and not a group of affiliated
entities. Both parties agree (that this GSMR section shall apply exclusively to
the Hospital Medical Segment. Both parties acknowledge and agree that the above
categories shall include the sales of calibrations and controls for each
respective testing category.

The parties agree to negotiate in
good faith additional incentive programs
designed to provide FHC with an increased GSMR if specific sales targets are
met for the D-dimer and Triage TOX Drug Screen Products.

 

 

4. Direct Distribution of
BNP Tests for Beckman Systems. As of the Amendment Date and
continuing for the remaining duration of the initial Term, Inverness may promote,
market sell and distribute the BNP Tests far Beckman Systems (the “ Beckman BNP”)
directly to customers within the Territory on its own or through an
affiliated entity or subsidiary of Inverness. From the Amendment Date
and for six (6) months thereafter, Inverness and FHC agree to use good faith
commercially reasonable
efforts to transition all Beckman BNP customers, excluding FHC contracted Beckman BNP
customers on FHC paperwork (“FHC Contracted Beckman BNP Customers”), from FHC to
Inverness for direct distribution and Inverness agrees that, during this
transition period, FHC will continue to receive a (GSMR of 11.0% on those Beckman BNP
accounts that it is still handling. Both parties agree that FHG shall not renew or
extend the term through an amendment, or fail to give notice of non-renewal or
otherwise of any FHC Contracted Beckman BNP Customer beyond the existing term in effect
as of the Amendment Date, and FHC may continue to promote, market, sell and distribute
Beckman BNP to FHC Contracted Beckman BNP Customers until the natural expiration of
their agreements. FHC agrees to take no action which would interfere with Inverness’
direct distribution efforts with Beckman BNP customers or with Invremess’s efforts to
develop and maintain the reputation of and goodwill with respect to
the Beckman BNP.
FHC will cease all sales and distribution of Beckman BNP during the Initial Term as
soon as the transition to Inverness is complete.

5. End
User Sales Performance Criteria If FHC’s aggregate end user sales for existing
Triage®
BNP Products (excluding end user sales of the Beckman BNP), DOA Products,
Triage® TOX Drug Screen Products and D-Dimer Product lines falls below the Minimum FHC
End User Sales for Co-Exclusivity for the applicable calendar year as identified in the
table below as determined by an end of year calendar review, then Inverness reserves
the right to give 180 days notice of its intention to terminate
FHC’s co-exclusive
distributor status following such annual review. If Inverness elects to terminate
FHC’s co-exclusivity under this clause and if Inverness subsequently elects to appoint
an additional distributor for the Products other than Inverness itself or its
affiliates, then Inverness agrees that any such distributor’s GSMR for the Products
shall not exceed the GSMR received by FHC in the 2006 Distribution Agreement for as
long as FHC’s purchases of the Products are equal to or superior than those made
by any such additional distributor. Whether or not the distributor status
of FHC is exclusive or co-exclusive, both parties acknowledge and agree that the
Non-Compete provision in Section 3(b) shall be effective without modification (unless
the parties mutually agree to an amendment) for as long as the 2006 Distribution
Agreement is in effect.

	 	 	 	 	 
	 	 	Minimum FHC End User Sales for	 
	Calendar Year	 	Co-Exclusivity	 
	 	 	 	 
	2009
	 		$124,500,000	 
	2010

	 		$114,100,000	 

If FHC’s aggregate end user sales for existing Triage® BNP Products (excluding end
user sales of the Beckman BNP), DOA Products, Triage® TOX Drug Screen Products and
D-Dimer Product lines falls below the Minimum FHC End User Sales for Inverness
Termination for the applicable calendar year as identified in the table below and as
determined by an end of year calendar review, then Inverness reserves the right to
give 180 days notice of its intention to terminate the 2006 Distribution Agreement
following such annual review.

	 	 	 	 	 
	 	 	Minimum FHC End User Sales For	 
	Calendar Year	 	Inverness Termination	 
	 	 	 	 
	2009
	 		$121,600,000	 
	2010
	 		$108,900,000	 

2

 

Inverness agrees that should it enter into any
new GPO  contract for the Products, then the minimum
sales levels defined above shall be reduced in proportion by any price discounts to products that
Inverness has elected to provide in any such contract.

6.
Limitation of Liability. Under no circumstances shall either party be liable to the other for
indirect or consequential damages, including lost profits, in
connection with this Amendment.

7. GSMR for “Uniquely New Products” and “Improved Products” Inverness and FHC acknowledge
and agree that the GSMR for Uniquely New Products and Improved Products shall be negotiated in good
faith between the parties at least thirty (30) days prior to the commercial release of any Uniquely New
Product or Improved Products. Inverness and FHC agree to delete any reference to “Increased Margin
Products” in the 2006 Distribution Agreement.

8.
Miscellaneous. Except as otherwise expressly modified by this
Amendment, the 2006 Distribution
Agreement shall remain in full force and effect in accordance with its existing terms. This Amendment
may be executed in two or more counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. In witness of their agreement to the
foregoing terms, the authorized representatives of each party have executed this Amendment effective as of
the Amendment Date.

	 	 	 
	INVERNESS MEDICAL INNOVATIONS
	 	 
	NORTH AMERICA, INC.

	 	Fisher Healthcare, a
	 

	 	division of Fisher Scientific
	 

	 	Company, L.L.C.
	 
	 	 
	By 

Title President
11 July 2008

	 	By 

Title President

         11 July 2008
	By 

Title Senior Vice Presidentexv10w30

Exhibit 10.30

INVERNESS MEDICAL INNOVATIONS, INC.

2001 STOCK OPTION AND INCENTIVE PLAN

NON-QUALIFIED STOCK OPTION AGREEMENT

FOR

NON-EMPLOYEE DIRECTORS

 

NON-QUALIFIED STOCK OPTION AGREEMENT

FOR NON-EMPLOYEE DIRECTORS

UNDER THE

INVERNESS MEDICAL INNOVATIONS, INC.

2001 STOCK OPTION AND INCENTIVE PLAN

	 	 	 	 	 
	Name of Optionee:
	 	 	 	 
	Number of Option Shares:

	 	 

	 	 
	 

	 	 	 	 
	Option Exercise Price Per Share:
	 	 	 	 
	 

	 	 	 	 
	Grant Date:
	 	 	 	 
	 

	 	 	 	 
	Expiration Date:
	 	 	 	 
	 

	 	 	 	 

     Pursuant to the Inverness Medical Innovations, Inc. 2001 Stock Option and Incentive Plan (the
“Plan”) as amended through the date hereof, Inverness Medical Innovations, Inc. (the “Company”)
hereby grants to the Optionee named above, who is a member of the Board of Directors of the Company
(a “Director”) but is not an employee of the Company, an option (the “Stock Option”) to purchase,
on or prior to the Expiration Date specified above, all or part of the number of Option Shares of
Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above at the Option
Exercise Price per Share specified above subject to the terms and conditions set forth herein and
in the Plan.

     1. Exercisability Schedule. No portion of this Stock Option may be exercised until
such portion shall have become exercisable. Except as set forth below, and subject to the
discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the
exercisability schedule hereunder, this Stock Option shall become exercisable with respect to the
following number of Option Shares on the dates indicated, so long as the Optionee remains a
Director of the Company:

	 	 	 	 	 	 	 	 	 
	 	 	Number of	 	Total Number of
	Exercisability	 	Option Shares First	 	Option Shares
	Date	 	Becoming Exercisable	 	Exercisable
	                     	 	 	                     (—	%)	 	 	                     (—	%)
	                     	 	 	                     (—	%)	 	 	                     (—	%)
	                     	 	 	                     (—	%)	 	 	                     (100	%)

     In the event of the termination of the Optionee’s service as a Director because of death, this
Stock Option shall become immediately exercisable in full, whether or not otherwise exercisable at
such time. Once exercisable, this Stock Option shall continue to be exercisable at

 

 

any time or times prior to the close of business on the Expiration Date, subject to the
provisions hereof and of the Plan.

     2. Manner of Exercise.

          (a) The Optionee may exercise this Option only in the following manner: from time to time on
or prior to the Expiration Date of this Option, the Optionee may give written notice to the
Administrator of his or her election to purchase some or all of the Option Shares purchasable at
the time of such notice. This notice shall specify the number of Option Shares to be purchased.

     Payment of the purchase price for the Option Shares may be made by one or more of the
following methods: (i) in cash, by certified or bank check or other instrument acceptable to the
Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that
have been purchased by the Optionee on the open market or that have been beneficially owned by the
Optionee for at least six months and are not then subject to restrictions under any Company plan;
(iii) by the Optionee delivering to the Company a properly executed exercise notice together with
irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and
acceptable to the Company to pay the option purchase price, provided that in the event the Optionee
chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply
with such procedures and enter into such agreements of indemnity and other agreements as the
Administrator shall prescribe as a condition of such payment procedure; or (iv) a combination of
(i), (ii) and (iii) above. Payment instruments will be received subject to collection.

     The delivery of certificates representing the Option Shares will be contingent upon the
Company’s receipt from the Optionee of full payment for the Option Shares, as set forth above and
any agreement, statement or other evidence that the Company may require to satisfy itself that the
issuance of Stock to be purchased pursuant to the exercise of Options under the Plan and any
subsequent resale of the shares of Stock will be in compliance with applicable laws and
regulations. In the event the Optionee chooses to pay the purchase price by previously-owned
shares of Stock through the attestation method, the number of shares of Stock transferred to the
Optionee upon the exercise of the Option shall be net of the Shares attested to.

          (b) Certificates for shares of Stock purchased upon exercise of this Stock Option shall be
issued and delivered to the Optionee upon compliance to the satisfaction of the Administrator with
all requirements under applicable laws or regulations in connection with such issuance and with the
requirements hereof and of the Plan. The determination of the Administrator as to such compliance
shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of,
or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock
Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof,
the Company shall have issued and delivered the shares to the Optionee, and the Optionee’s name
shall have been entered as the stockholder of record on the books of the Company. Thereupon, the
Optionee shall have full voting, dividend and other ownership rights with respect to such shares of
Stock.

 

 

          (c) The minimum number of shares with respect to which this Stock Option may be exercised at
any one time shall be 10 shares, unless the number of shares with respect to which this Stock
Option is being exercised is the total number of shares subject to exercise under this Stock Option
at the time.

          (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option
shall be exercisable after the Expiration Date hereof.

     3. Termination of Service to the Company. If the Optionee ceases to provide services
to the Company as a Director or an employee, the period within which to exercise the Stock Option
may be subject to earlier termination as set forth below.

          (a) Termination For Cause. If the Optionee ceases to be a Director or employee for
Cause, any Stock Option held by the Optionee shall immediately terminate and be of no further force
and effect. For purposes hereof, “Cause” shall mean: (i) any material breach by the Optionee of
any agreement between the Optionee and the Company; (ii) the conviction of or plea of nolo
contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material
misconduct or willful and deliberate non-performance (other than by reason of disability) by the
Optionee of the Optionee’s duties to the Company.

          (b) Termination by Reason of Death. If the Optionee ceases to be a Director or
employee by reason of death, any Stock Option granted to the Optionee as a Director and held by the
Optionee at the date of death may be exercised by his or her legal representative or legatee for a
period of twelve months from the date of death or until the Expiration Date, if earlier.

          (c) Other Termination. If the Optionee ceases to be a Director or employee for any
reason other than Cause or death, any Stock Option granted to the Optionee as a Director and held
by the Optionee on the date of termination or service may be exercised for a period of six months
from the date of termination or until the Expiration Date, if earlier; provided that if the
Optionee ceases to be a Director or employee by reason of voluntary retirement (as determined by
the Administrator) after the age of 58 then Options exercisable on the date of termination be
exercised for a period of twelve months from the date of termination or until the Expiration Date,
if earlier.

     4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock
Option shall be subject to and governed by all the terms and conditions of the Plan. Capitalized
terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is
specified herein.

     5. Transferability. This Agreement is personal to the Optionee, is non-assignable and
is not transferable in any manner, by operation of law or otherwise, other than by will or the laws
of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime,
only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.
Notwithstanding the foregoing, to the extent that any portion of this Stock Option exceeds the
$100,000 limitation described in Section 422(d) of the Internal Revenue Code of 1986, as amended
(the “Code”), such portion shall be deemed a non-qualified Stock Option and may be transferred,
upon approval of the Administrator following submission of a petition for

 

 

such transfer from the Optionee to the Administrator and the written agreement of the proposed
transferee to be bound by the terms of the Plan and this Agreement, to the Optionee’s spouse,
children (natural or adopted) or stepchildren, a trust for the sole benefit of one or more such
family members of which the Optionee is the settlor, or a family limited partnership or family
limited liability company of which the limited partners or members, as the case may be, consist
solely of one or more such family members.

     6. Miscellaneous.

          (a) Notice hereunder shall be given to the Company at its principal place of business, and
shall be given to the Optionee at the address set forth below, or in either case at such other
address as one party may subsequently furnish to the other party in writing.

          (b) This Stock Option does not confer upon the Optionee any rights with respect to continuance
of employment by the Company or any Subsidiary.

—Signature page follows—

 

 

	 	 	 	 	 	 	 
	 

	 	For:	 	INVERNESS MEDICAL 

INNOVATIONS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	
 
Title: Treasurer	 	 

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by
the undersigned.

	 	 	 	 	 	 	 	 	 
	Dated:
	 	 	 	 	 	 	 	 
	 
	 	
 
	 	 	 	 

Optionee’s Signature	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	Optionee’s name and address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]